Last reviewed · How we verify

NCT07257289: PREVENT

Stratification of Arrhythmic Risk and/or Heart Failure Risk in Patients With Hereditary Heart Disease

Recruiting now Last updated 27 March 2026
What this trial tests

trial in Hereditary Heart Diseases in 1,000 participants. Currently enrolling.

Timeline
3 February 2026
Primary endpoint
3 February 2036
12 December 2036

Quick facts

Lead sponsorNantes University Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment1,000
Start date3 February 2026
Primary completion3 February 2036
Estimated completion12 December 2036
Sites15 locations across Martinique, France, Reunion

Conditions studied

Sponsor

Nantes University Hospital

Who can join

Adults 1 to 100, any sex, with Hereditary Heart Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Sudden cardiac death (SCD) is one of the leading causes of death in developed countries. These deaths (more than 5,000 per year in France) are due to hereditary arrhythmias or cardiomyopathies. Early diagnosis of SCD is often achieved through family screening, but the main challenge is to stratify the risk of SCD in these patients. Indeed, prevention of SCD relies mainly on the implantation of an automatic defibrillator. The challenge is to identify patients who will develop SCD and avoid implanting an implantable cardioverter defibrillator (ICD) in patients who will never develop arrhythmias but who will face complications related to the ICD (inappropriate shocks, infection, lead failure), leading to a reduced quality of life and significant costs for the healthcare system. However, there is a lack of relevant clinical and biological markers for risk stratification, which rules out any possibility of preventive screening. Most of the clinical and ECG (electrocardiogram) parameters identifying an increased risk of SCD have not been reproduced in replication studies. In this project, the investigator will develop a data processing and analysis pipeline using artificial intelligence methods to assess the individual risk of serious arrhythmic events or heart failure in patients with hereditary arrhythmic diseases or cardiomyopathies through the automated processing of multimodal data (clinical data, electrocardiogram (ECG), imaging (echocardiography, MRI magnetic resonance imaging), genetic data, biomarkers).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Nantes University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07257289.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing